TRAIL-based therapeutics have shown great potential in pre-clinical studies as a novel approach for the treatment of GBM [45,46,47] but the BBB prevents the entry of TRAIL-based biologics from effectively reaching GBM tumours. This evidence concerns the gene TNFSF10 and glioblastoma.